Strategic Partnerships USDTL has demonstrated a pattern of forming strategic partnerships and investments, including a partnership with CourtFact Technologies in early 2026 and a funding round with Northlane Capital Partners in 2025, signaling a favorable openness to collaborations and expansion through alliances.

Expansion Focus Recent leadership changes and investment activity indicate a growth trajectory aimed at expanding capabilities and geographic reach, presenting opportunities to position USDTL as a preferred partner for scaling substance abuse testing programs in healthcare, corrections, and defense sectors.

Diverse Testing Capabilities USDTL offers advanced specimen options (hair, fingernail, umbilical cord, meconium) and broad panel testing including ambiguous substances, plus perinatal and newborn exposure testing, enabling cross-selling across healthcare facilities, child protection agencies, legal services, and research organizations.

Accreditations & Quality As an ISO 170125 internationally accredited forensic laboratory with multiple certifications, USDTL can be positioned to higher-risk, regulated environments and healthcare providers seeking compliant, proven testing providers for sensitive substance abuse programs.

Industry Demand Signals The client base spans healthcare facilities, child protection agencies, Department of Defense, and legal services, indicating recurring demand from government and regulated sectors for compliant toxicology testing, which aligns with opportunities for managed services, volume contracts, and integrated testing workflows.